Figure 1.

Mean HbA_1c over time. During run-in, observed mean HbA_1c was reduced from 7.8% (61.3 mmol/mol) to 7.6% (59.3 mmol/mol) for participants subsequently randomized to mealtime faster aspart, from 7.7% (60.4 mmol/mol) to 7.5% (58.8 mmol/mol) for those randomized to mealtime IAsp, and from 7.7% (60.8 mmol/mol) to 7.6% (59.4 mmol/mol) for those randomized to postmeal faster aspart. At the end of the 26-week treatment period, mean HbA_1c was 7.6% (59.9 mmol/mol), 7.8% (61.3 mmol/mol), and 7.9% (63.0 mmol/mol) in the mealtime faster aspart, mealtime IAsp, and postmeal faster aspart arms, respectively. Faster aspart (mealtime): IAsp (mealtime) ETD at week 26 –0.17% (95% CI −0.30; −0.03), *P = 0.014. Faster aspart (postmeal): IAsp (mealtime) ETD at week 26 0.13% (95% CI –0.01; 0.26), P = 0.061. Noninferiority of mealtime and postmeal faster aspart versus mealtime IAsp confirmed (P value from the one-sided test for noninferiority with 0.4% margin evaluated at the 2.5% level: P < 0.001). Error bars: ±SE. All available information regardless of treatment discontinuation was used.